Top Celgene exec pins the blame for ozanimod fiasco on the Receptos team — acquired 3 years ago
Celgene’s top execs have been reeling for months, staggered by the FDA’s decision to kick back their application on ozanimod, the big drug in the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
